Biologics License Application (BLA)
The regulatory application submitted to the FDA for approval of biological products such as vaccines, gene therapies, and monoclonal antibodies.
In Detail
A Biologics License Application (BLA) is the regulatory submission required for FDA approval of biological products, a category that includes vaccines, blood products, gene therapies, cellular therapies, monoclonal antibodies, and other treatments derived from living organisms. While the NDA covers traditional small-molecule drugs, the BLA covers biologics, which are typically larger, more complex molecules produced through biotechnology processes. The BLA submission includes comprehensive data from preclinical and clinical studies demonstrating the product's safety, purity, and potency, as well as detailed information about the manufacturing process. Manufacturing is particularly critical for biologics because they are produced by living cells, making the production process inherently more complex and variable than traditional drug manufacturing. The FDA reviews BLAs through a process similar to NDA review, with a standard timeline of 10-12 months and a priority review option of 6-8 months. The Center for Biologics Evaluation and Research (CBER) reviews most BLAs, though some therapeutic biologics are reviewed by the Center for Drug Evaluation and Research (CDER). Biologics represent a growing share of new approvals, many of the most innovative treatments in oncology, immunology, and rare diseases are biologics. The Biologics Price Competition and Innovation Act (BPCIA) created a pathway for biosimilars, which are analogous to generic drugs but for biologics. Understanding the BLA pathway is increasingly important as biologic therapies become more prevalent in clinical trials.
Frequently Asked Questions
What does "Biologics License Application (BLA)" mean in clinical trials?
The regulatory application submitted to the FDA for approval of biological products such as vaccines, gene therapies, and monoclonal antibodies.
Why is "biologics license application (bla)" important for patients?
Understanding biologics license application (bla) helps patients and caregivers navigate clinical trial participation with confidence. It is part of the broader clinical research process that ensures treatments are safe and effective before reaching patients.
Related Terms
New Drug Application (NDA)
The formal application submitted to the FDA after clinical trials are complete, requesting approval to market a new drug for sale in the United States.
FDA Approval Process
The regulatory pathway through which the U.S. Food and Drug Administration evaluates and approves new drugs, biologics, and medical devices for public use.
Clinical Trial
A research study that tests a medical treatment, drug, device, or intervention in human volunteers to determine whether it is safe and effective.
this entity is one of the U.S. clinical trials and research registries concepts that recurs across this site. The definition above is the technical answer; the paragraphs below add the practical context for how the concept connects to the the NIH ClinicalTrials.gov registry data behind every per-entity page on the site.
In the the NIH ClinicalTrials.gov registry data, this concept shapes one or more of the fields that drive the per-entity grades and rankings on this site. The methodology page describes which fields feed into which output; this glossary entry documents the underlying term.
Source: ClinicalTrials.gov, 2026.